Concurrent RUNX1::MECOM and RUNX1::PRDM16 Fusions from a Novel Genomic Breakpoint: First Report of a Dual-Fusion Mechanism in Acute Myeloid Leukemia.

Authors

Siyu Chen, Shengwang Wu, Jing Zhang, Xing Qiang, Siheng Liu, Wuchen Yang, Xiangui Peng, Xi Zhang, Jun Ren, Cheng Zhang

Published in

OncoTargets and therapy. Volume 19. Pages 635500. Epub Sep 16, 2026.

Abstract

While complex fusions involving three chromosomes are already uncommon in AML, the formation of two distinct fusion genes from an identical breakpoint is exceptionally rare. This paper reports the adult case of acute myeloid leukemia harboring dual fusion genes RUNX1::MECOM and RUNX1::PRDM16, both originating from the same RUNX1 breakpoint (chr21:36206707, hg19). The 62-year-old male patient presented with primary refractory acute myeloid leukemia (AML), failed to achieve remission after induction chemotherapy, and had an overall survival of only 3 months. The RUNX1::PRDM16 translocation was cryptic and resulted in PRDM16 overexpression, which is associated with poor prognosis. Integrated molecular profiling revealed concurrent mutations in FLT3-ITD, U2AF1, and PTPN11, collectively indicating a very high disease risk. This case provides the first evidence for the novel mechanism of dual fusion gene formation from a single genomic breakpoint.

PMID:
42764945
Bibliographic data and abstract were imported from PubMed on 21 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.